Venetoclax is a highly selective Bcl-2 inhibitor with FDA approval for patients with chronic lymphatic leukaemia (CLL) with an established clinical safety profile [38]. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.